PIOMBINO DESE, Italy – Stevanato Group S.p.A. (NYSE: STVN), a outstanding supplier of drug containment and supply options, has introduced the pricing of its upsized public share providing at $26 per share. The providing consists of 12,700,000 odd shares, with half being offered by the corporate and half by Stevanato Holding S.r.l., a serious shareholder.

The full gross proceeds are anticipated to achieve roughly $330 million earlier than deductions. Moreover, underwriters have a 30-day choice to buy as much as 1,905,000 additional shares on the identical phrases.

The corporate goals to allocate the web proceeds from its portion of the providing in the direction of basic company functions, together with funding actions and dealing capital wants. Stevanato Group won’t profit financially from the shares offered by Stevanato Holding.

The providing is scheduled to shut on March 26, 2024, contingent upon customary closing circumstances. Morgan Stanley and William Blair are main the underwriting staff, with BofA Securities, Citigroup, and KeyBanc Capital Markets additionally taking part as joint book-runners.

This transfer comes as a part of an computerized shelf registration assertion filed with the SEC on March 20, 2024, and the shares can be supplied by way of a prospectus complement and accompanying prospectus. The transaction is topic to regulatory compliance and isn’t a proposal to promote or a solicitation of a proposal to purchase in any jurisdiction the place such actions could be illegal.

Stevanato Group, based in 1949, providers the pharmaceutical, biotechnology, and life sciences sectors with its complete suite of merchandise and engineering options, supporting shoppers all through the drug lifecycle.

The knowledge for this text is predicated on a press launch assertion from Stevanato Group S.p.A.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.